Clinical trial · Interventional
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab
NCT01707628CI-TRIAL-00013634RituxivaccompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. Secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Hodgkin Lymphoma (NHL) | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| influenza vaccination with influenza vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Early group after rituximab
- description
- Patients who received rituximab last dose 3-6 months before influenza vaccination will be the "early group".
- interventionNames
- Biological: influenza vaccination with influenza vaccine
- type
- ACTIVE_COMPARATOR
- label
- Late group after rituximab
- description
- Patients who received rituximab last dose 9-12 months before influenza vaccination will be the "late group".
- interventionNames
- Biological: influenza vaccination with influenza vaccine
- type
- ACTIVE_COMPARATOR
- label
- Control group
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with non-Hodgkin's lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission. 2. Completion of rituximab therapy in the last twelve months before start of the study. 3. Age ≥ 18 years. 4. Signing of informed consent. Exclusion Criteria: 1. Completion of rituximab therapy 7-8 months before start of the study. 2. Fever at time of vaccination. 3. Previous/known allergic reaction to any of the components of the vaccines given.
References
Publications (0)
Data not yet available
No reference posted for this study.